Focused On-demand Library for Receptor-type tyrosine-protein phosphatase C

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P08575

UPID:

PTPRC_HUMAN

Alternative names:

Leukocyte common antigen; T200

Alternative UPACC:

P08575; A0A0A0MT22; A8K7W6; Q16614; Q9H0Y6; X6R433

Background:

Receptor-type tyrosine-protein phosphatase C, also known as Leukocyte common antigen or T200, plays a pivotal role in T-cell activation and immune response regulation. It acts as a positive regulator of T-cell coactivation upon binding to DPP4 and modulates the activity of several kinases, including LYN and FYN, crucial for T-cell function.

Therapeutic significance:

Given its critical role in T-cell activation and its involvement in diseases like Multiple sclerosis and Immunodeficiency 105, targeting Receptor-type tyrosine-protein phosphatase C could offer novel therapeutic avenues. Understanding its function and interaction pathways opens doors to potential strategies for modulating immune responses in these conditions.